BioVie Enrolls First Patient In Phase 2 ADDRESS-LC Clinical Trial Evaluating Bezisterim For Treatment Of Neurological Symptoms Associated With Long COVID; Expects Topline Data To Be Available In H1 2026

Despite growing recognition of long COVID as a serious condition, diagnosed patients have no approved treatment options, with many suffering from debilitating fatigue and brain fog

Evidence suggests sustained inflammation plays a central role in the pathogenesis of long COVID, particularly in the associated cognitive dysfunction and other neurological symptoms1

Bezisterim targets key underlying mechanisms of neuroinflammation, and has demonstrated the potential to reduce chronic symptoms in Alzheimer's disease and Parkinson's disease trials thought to be driven by neuroinflammation

CARSON CITY, Nev., May 15, 2025 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ:BIVI), ("BioVie" or the "Company"), a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced first patient enrollment in the Phase 2 ADDRESS-LC clinical trial (NCT06847191) evaluating bezisterim (NE3107) for the treatment of neurological symptoms associated with long COVID. The Company anticipates topline data to be available in the first half of 2026.

Long COVID affects approximately 20 million adults in the US, and millions more worldwide.2,3 Studies estimate that approximately 10-30% of individuals who contract COVID-19 experience lingering symptoms for months or even years, with fatigue, brain fog, and cognitive impairment significantly impacting daily functioning and quality of life.4,5 Despite the growing recognition of long COVID as a serious condition, treatment options remain limited, and many patients struggle to find effective relief for their symptoms.